Australian Clinical Labs Limited (ASX: ACL)

Market Cap	692.38M
Revenue (ttm)	696.37M
Net Income (ttm)	23.93M
Shares Out	199.53M
EPS (ttm)	0.12
PE Ratio	28.92
Forward PE	17.97
Dividend	0.12 (3.51%)
Ex-Dividend Date	Sep 4, 2024

Volume	562,593
Open	3.440
Previous Close	3.420
Day's Range	3.380 - 3.480
52-Week Range	2.140 - 3.855
Beta	1.18
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 26, 2025

About Australian Clinical Labs

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offe...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 4,900
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACL

Financial Performance

In 2024, Australian Clinical Labs's revenue was 696.37 million, a decrease of -0.10% compared to the previous year's 697.07 million. Earnings were 23.93 million, a decrease of -33.33%.